Nature Biotechnology

Consortia and commodities

Nature Biotechnology 28, 629 (2010). doi:10.1038/nbt0710-629

The rise of open source drug R&D in consortia involving big pharma should prompt some biotech companies to re-examine their businesses.

Pharma embraces open source models

Nature Biotechnology 28, 631 (2010). doi:10.1038/nbt0710-631

Author: Stephen Strauss

New eyes on old drugs

Nature Biotechnology 28, 633 (2010). doi:10.1038/nbt0710-633a

Author: Stephen Strauss

Genetic testing clamp down

Nature Biotechnology 28, 633 (2010). doi:10.1038/nbt0710-633b

Author: Malorye Allison

New tech transfer models gain traction with deal flow

Nature Biotechnology 28, 634 (2010). doi:10.1038/nbt0710-634

Author: John Hodgson

French IPO spate

Nature Biotechnology 28, 635 (2010). doi:10.1038/nbt0710-635b

Author: Emma Dorey

Industrial biotech to boom?

Nature Biotechnology 28, 635 (2010). doi:10.1038/nbt0710-635c

Author: Daniel Grushkin

Sequencing firms vie for diagnostics market, tiptoe round patents

Nature Biotechnology 28, 635 (2010). doi:10.1038/nbt0710-635a

Author: Michael Eisenstein

Merck ditches biogeneric

Nature Biotechnology 28, 636 (2010). doi:10.1038/nbt0710-636a

Author: Emma Dorey

Investors fight Charles River/WuXi merger

Nature Biotechnology 28, 636 (2010). doi:10.1038/nbt0710-636b

Author: Suzanne Elvidge

Genzyme partners TJAB

Nature Biotechnology 28, 637 (2010). doi:10.1038/nbt0710-637b

Author: Jennifer Rohn

China's heparin billionaires

Nature Biotechnology 28, 637 (2010). doi:10.1038/nbt0710-637c

Author: Hepeng Jia

Microcap public biotechs access new pool of VC funding

Nature Biotechnology 28, 637 (2010). doi:10.1038/nbt0710-637a

Author: Peter Mitchell

Italian GM rebels

Nature Biotechnology 28, 638 (2010). doi:10.1038/nbt0710-638

Author: Anna Meldolesi

Newsmaker: Agios Pharmaceuticals

Nature Biotechnology 28, 639 (2010). doi:10.1038/nbt0710-639

Author: Joe Alper & Lisa Melton

Agios has brought cancer metabolism into vogue and is making hay from tumor cells' well-known hunger for glucose.

Drug pipeline: Q210

Nature Biotechnology 28, 640 (2010). doi:10.1038/nbt0710-640

Author: Wayne Peng

Sunshine on conflicts

Nature Biotechnology 28, 641 (2010). doi:10.1038/nbt0710-641

Author: Virginia Hughes

US drug companies are preparing for new draconian provisions for reporting on financial relationships with academia. Will efforts to increase transparency prove burdensome to researchers and the industry? Virginia Hughes investigates.

PeptideClassifier for protein inference and targeted quantitative proteomics

Nature Biotechnology 28, 647 (2010). doi:10.1038/nbt0710-647

Authors: Ermir Qeli & Christian H Ahrens

Minimum information about a protein affinity reagent (MIAPAR)

Nature Biotechnology 28, 650 (2010). doi:10.1038/nbt0710-650

Authors: Julie Bourbeillon, Sandra Orchard, Itai Benhar, Carl Borrebaeck, Antoine de Daruvar, Stefan Dübel, Ronald Frank, Frank Gibson, David Gloriam, Niall Haslam, Tara Hiltker, Ian Humphrey-Smith, Michael Hust, David Juncker, Manfred Koegl, Zoltàn Konthur, Bernhard Korn, Sylvia Krobitsch, Serge Muyldermans, Per-Åke Nygren, Sandrine Palcy, Bojan Polic, Henry Rodriguez, Alan Sawyer, Martin Schlapshy, Michael Snyder, Oda Stoevesandt, Michael J Taussig, Markus Templin, Matthias Uhlen, Silvere van der Maarel, Christer Wingren, Henning Hermjakob & David Sherman

Guidelines for reporting the use of column chromatography in proteomics

Nature Biotechnology 28, 654 (2010). doi:10.1038/nbt0710-654a

Authors: Andrew R Jones, Kathleen Carroll, David Knight, Kirsty MacLellan, Paula J Domann, Cristina Legido-Quigley, Lihua Huang, Lance Smallshaw, Hamid Mirzaei, James Shofstahl & Norman W Paton